MX2016005287A - Metodos para el tratamiento de distrofias musculares. - Google Patents

Metodos para el tratamiento de distrofias musculares.

Info

Publication number
MX2016005287A
MX2016005287A MX2016005287A MX2016005287A MX2016005287A MX 2016005287 A MX2016005287 A MX 2016005287A MX 2016005287 A MX2016005287 A MX 2016005287A MX 2016005287 A MX2016005287 A MX 2016005287A MX 2016005287 A MX2016005287 A MX 2016005287A
Authority
MX
Mexico
Prior art keywords
treatment
methods
muscular dystrophies
composition
dystrophy
Prior art date
Application number
MX2016005287A
Other languages
English (en)
Inventor
Sylvie Namour Florence
Peixoto Christophe
D Bush Ernest
Nique Francois
Jagerschmidt Catherine
Blanque Roland
Michael Lefrancois Jean-
Deprez Pierre
Triballeau Nicolas
Tom Burt Paul Wigerinck Piet
Original Assignee
D Bush Ernest
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by D Bush Ernest filed Critical D Bush Ernest
Publication of MX2016005287A publication Critical patent/MX2016005287A/es

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/4164—1,3-Diazoles
    • A61K31/4166—1,3-Diazoles having oxo groups directly attached to the heterocyclic ring, e.g. phenytoin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/04—Drugs for disorders of the muscular or neuromuscular system for myasthenia gravis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/02—Nutrients, e.g. vitamins, minerals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical & Material Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Epidemiology (AREA)
  • Neurology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Nutrition Science (AREA)
  • Rheumatology (AREA)
  • Physiology (AREA)
  • Pain & Pain Management (AREA)
  • Pulmonology (AREA)
  • Obesity (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Hematology (AREA)
  • Diabetes (AREA)
  • Biomedical Technology (AREA)
  • Neurosurgery (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)

Abstract

La presente invención se relaciona con, inter alia, el tratamiento de distrofia muscular (por ejemplo, Distrofia Muscular de Duchenne), por ejemplo, utilizando una composición, por ejemplo, una composición que comprende el Compuesto (I), o una sal farmacéuticainente aceptable, profármaco o metabolito del mismo.
MX2016005287A 2013-10-25 2014-10-24 Metodos para el tratamiento de distrofias musculares. MX2016005287A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201361895832P 2013-10-25 2013-10-25
PCT/US2014/062178 WO2015061685A1 (en) 2013-10-25 2014-10-24 Methods for treatment of muscular dystrophies

Publications (1)

Publication Number Publication Date
MX2016005287A true MX2016005287A (es) 2017-02-22

Family

ID=52993619

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2016005287A MX2016005287A (es) 2013-10-25 2014-10-24 Metodos para el tratamiento de distrofias musculares.

Country Status (9)

Country Link
US (2) US20160250188A1 (es)
EP (1) EP3060206A4 (es)
JP (1) JP2016538269A (es)
CN (1) CN105979943A (es)
AU (1) AU2014339917A1 (es)
BR (1) BR112016009214A8 (es)
CA (1) CA2928235A1 (es)
MX (1) MX2016005287A (es)
WO (1) WO2015061685A1 (es)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2643856B1 (es) 2016-05-24 2018-08-03 Universidad Del Pais Vasco / Euskal Herriko Unibertsitatea Triazoles para la regulación de la homeostasis de calcio intracelular
EP3585420A4 (en) * 2017-02-22 2021-04-07 Bioincept LLC PEPTIDES AND METHODS OF TREATMENT OF DYSTROPHY RELATED CONDITIONS USING THEM
US20210361635A1 (en) * 2018-06-05 2021-11-25 The Regents Of The University Of California Methods for treating muscular dystrophies
CN113924085A (zh) * 2019-04-12 2022-01-11 加利福尼亚大学董事会 用于增加肌肉量和氧化代谢的组合物和方法

Family Cites Families (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0715087D0 (en) * 2007-08-03 2007-09-12 Summit Corp Plc Drug combinations for the treatment of duchenne muscular dystrophy
GB2463514C (en) * 2008-09-11 2018-09-26 Galapagos Nv Imidazolidine compounds and uses therefor
ITBO20090078A1 (it) * 2009-02-13 2010-08-14 Consiglio Nazionale Ricerche Composti per il trattamento del tumore alla prostata e procedimenti per la loro sintesi

Also Published As

Publication number Publication date
WO2015061685A1 (en) 2015-04-30
US20160250188A1 (en) 2016-09-01
EP3060206A1 (en) 2016-08-31
JP2016538269A (ja) 2016-12-08
US20190167640A1 (en) 2019-06-06
CA2928235A1 (en) 2015-04-30
AU2014339917A1 (en) 2016-05-12
BR112016009214A8 (pt) 2020-03-24
CN105979943A (zh) 2016-09-28
EP3060206A4 (en) 2017-04-19

Similar Documents

Publication Publication Date Title
PH12019501321A1 (en) Methods of treating or preventing cholesterol related disorders
PH12015502031B1 (en) Tetrahydropyrrolothiazine compounds
PH12016500169A1 (en) Polymorph of syk inhibitors
UA117976C2 (uk) Сполуки амінопіримідинілу як інгібітори jak
MX2015011913A (es) Moduladores de acido oxabiciclo[2.2.2] gpr120.
MX2015005858A (es) Moduladores del receptor acoplado a proteina g (gpr40) de dihidropirazol.
MX2016006336A (es) Compuestos pirazolopirimidina.
MX361499B (es) Baricitinib deuterado.
MY197698A (en) Oxysterols and methods of use thereof
MX358499B (es) Moduladores de dihidropirazol del receptor acoplado a la proteína g (gpr40).
MX2015005720A (es) Moduladores de dihidropirazol de receptor acoplado a la proteina g (gpr40).
NZ729037A (en) Carboxylic acid compound, method for preparation thereof, and use thereof
IN2015DN00598A (es)
MX2015011932A (es) Moduladores de gpr120 de acido biciclo[2.2.2].
MY187718A (en) Pharmaceutical formulations
EA201490756A1 (ru) Разагилина цитрамид
MX2015015562A (es) Dihidropiridinona como inhibidores de monoacilglicerol aciltransferasa 2.
MX2016010973A (es) Compuestos de aminocarbonilcarbamato.
MY162886A (en) Novel tetrahydropyridopyrimidine compound or salt thereof
MX362879B (es) Usos novedosos.
PH12018500903A1 (en) Pyranodipyridine compound
IN2014DN07996A (es)
MX2015011375A (es) Moduladores del receptor acoplado a proteina-g 120 (gpr120) de acido biciclo-[2.2.1].
JOP20200030A1 (ar) مركب خماسي الحلقة
MX2016005287A (es) Metodos para el tratamiento de distrofias musculares.